Mumbai, Maharashtra, India India Alternatives Private Equity Fund appeared to be the VC, which was created in 1977. The main office of represented VC is situated in the Mumbai. The company was established in Asia in India.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Cyber Security, Security. Among the most popular portfolio startups of the fund, we may highlight Seclore. Besides, a startup needs to be aged 11-15 years to get the investment from the fund.
This India Alternatives Private Equity Fund works on 12 percentage points less the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2019. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 63 percentage points more often commits exit comparing to other companies.
The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the India Alternatives Private Equity Fund, startups are often financed by VenturEast, Tata Capital, Helion Venture Partners. The meaningful sponsors for the fund in investment in the same round are VenturEast, Sistema Asia Fund, IIFL.
Related Funds
| Fund Name | Location |
| Acuitas Investments | Seattle, United States, Washington |
| BKO Capital | Colorado, Highlands Ranch, United States |
| DMI Alternatives | Delhi, India, New Delhi |
| Harte Hanks | San Antonio, Texas, United States |
| KKP Capital | - |
| Liberty Technology Venture Capital | Colorado, Englewood, United States |
| Norrland Fund | - |
| Pacific Corporate Group | California, La Jolla, United States |
| Rob Harris | - |
| Sparkasse Jena | Germany, Jena, Thuringia |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Kapture | $4M | 20 Dec 2023 | Houston, Texas, United States | ||
Gynoveda | $10M | 15 Mar 2023 | Mumbai, Maharashtra, India | ||
Brinton Pharmaceuticals | $8M | 15 Jun 2019 | Redding, California, United States | ||
Seclore | $12M | 27 Apr 2016 | Sunnyvale, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Kapture | $4M | 20 Dec 2023 | Houston, Texas, United States | ||
Gynoveda | $10M | 15 Mar 2023 | Mumbai, Maharashtra, India | ||
Brinton Pharmaceuticals | $8M | 15 Jun 2019 | Redding, California, United States | ||
Seclore | $12M | 27 Apr 2016 | Sunnyvale, California, United States |
